AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026Business Wire • 06/30/26
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)Business Wire • 06/17/26
AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks TranscriptSeeking Alpha • 06/10/26
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes EffectBusiness Wire • 05/28/26
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness Wire • 05/27/26
Wall Street Analysts See a 50.5% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?Zacks Investment Research • 05/22/26
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate CancerBusiness Wire • 05/13/26
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a BetZacks Investment Research • 05/06/26
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to TradeZacks Investment Research • 04/20/26
AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 04/10/26
ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin DownZacks Investment Research • 04/06/26
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued ProfitabilityBusiness Wire • 04/02/26
AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness Wire • 03/31/26
AngioDynamics to Present at the Leerink Partners Global Healthcare ConferenceBusiness Wire • 02/23/26
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation PlatformBusiness Wire • 02/19/26
Does AngioDynamics (ANGO) Have the Potential to Rally 92.15% as Wall Street Analysts Expect?Zacks Investment Research • 02/06/26